Clinical Trials
75 trialsPreventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy
University of British Columbia
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
HYPNO-AJA2
Institut Bergonié
ADAPT-OC
Queen's University
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
Tongji Hospital
RESO
Zhejiang Cancer Hospital
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
University of California, Irvine
E-FACTOR
Centre Leon Berard
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Shanghai Municipal Hospital of Traditional Chinese Medicine
PITCH - Impacting Hereditary Cancer Testing
University of Kentucky
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
YS247
Peking University Third Hospital
EORTC QOL-OV39
Helios University Hospital Wuppertal
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
DETERMINE
Cancer Research UK
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Zhejiang University
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NACT-KELIM ID
Aristotle University Of Thessaloniki
The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients
Far Eastern Memorial Hospital
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
CALM-TF
University Health Network, Toronto
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
Visual-PC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
PONDER
Ospedale Santa Croce-Carle Cuneo
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
Seoul National University Hospital
Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
Tongji Hospital
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
National Cancer Institute, Naples
PANtHer-AI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
COSMOS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Shandong University
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Oncare Madrid
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Seoul National University Hospital
MISSION-2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ultra-teaching
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Tongji Hospital
Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
Fudan University
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
University of South Florida
INOCA
Istanbul University
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
Peking University
ACT-Based Nursing Intervention for Ovarian Cancer Patients: A Pilot Study
Yonsei University